Last reviewed · How we verify
RT+CDDP/5-FU
RT+CDDP/5-FU is a combination chemotherapy regimen that works by inhibiting DNA replication and interfering with DNA repair, ultimately leading to cell death.
RT+CDDP/5-FU is a combination chemotherapy regimen that works by inhibiting DNA replication and interfering with DNA repair, ultimately leading to cell death. Used for Metastatic colorectal cancer, Metastatic gastric cancer.
At a glance
| Generic name | RT+CDDP/5-FU |
|---|---|
| Also known as | Radiotherapy, Cisplatin, 5-fluoruracil |
| Sponsor | Associazione Volontari Pazienti Oncologici |
| Drug class | Platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
RT (radiation therapy) targets rapidly dividing cancer cells by damaging their DNA, while CDDP (cisplatin) interferes with DNA repair mechanisms, making it difficult for cancer cells to repair DNA damage. 5-FU (5-fluorouracil) is a thymidylate synthase inhibitor that disrupts DNA synthesis, further contributing to cell death.
Approved indications
- Metastatic colorectal cancer
- Metastatic gastric cancer
Common side effects
- Nausea and vomiting
- Diarrhea
- Fatigue
- Anemia
- Neutropenia
- Thrombocytopenia
Key clinical trials
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA (PHASE2, PHASE3)
- A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
- Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer (PHASE2)
- Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck (PHASE3)
- A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer (PHASE2)
- Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RT+CDDP/5-FU CI brief — competitive landscape report
- RT+CDDP/5-FU updates RSS · CI watch RSS
- Associazione Volontari Pazienti Oncologici portfolio CI